Krishna Institute of Medical Sciences (KIMS): 19% ROE, 81x P/E – Healthcare Growth or Investor Fever?

At a Glance

KIMS, the corporate hospital giant of Andhra and Telangana, continues to flex its regional dominance. Revenue soared 26.8% YoY in Q1 FY26, but PAT dropped to ₹85 Cr (a 9% decline QoQ). Stock trades at a nosebleed P/E of 81.4, priced as if it’s Apollo 2.0. Promoter holding fell by 4.7%, so even insiders might be saying, “Bas karo, yaar.” Is this growth story still healthy, or are investors on an expensive IV drip?

Introduction

Hospitals are like airports: packed, overpriced, and you have no choice but to pay. KIMS is cashing in on this, running 12 hospitals with over 4,000 beds, offering everything from primary to quaternary care. They’ve built their empire in tier-2/3 cities, where competition snoozes, and patients line up.

But here’s the catch – while revenues surge, earnings are flattening, capex is ballooning, and valuations have a fever. Let’s dissect this patient (err, stock) with a scalpel.

Business Model (WTF Do They Even Do?)

• Core: Operates a chain of multi-specialty hospitals across South India.
• Strategy: Low-cost tertiary care in non-metros, premium care in metros.
• Edge: Strong doctor network, operational efficiency, and regional dominance.
• Revenue Mix: IPD (in-patient) > OPD (outpatient), with super-specialty surgeries being the cash cows.

Translation: They make money by treating everything – from heart attacks to headaches – at scale.

Financials Overview

Observation: Great top-line growth, consistent margins,